Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses alternative therapies to the acute kidney injury-causing combination of vancomycin piperacillin/tazobactam.
Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains that hepatitis C infection awareness has been on the rise in the United States.
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains why it’s important to understand the prevalence of skin and soft tissue infections.
Oluwatoyin (Toyin) Adeyemi, MD, attending physician of infectious diseases, at Cook County Health and Hospital System, discusses the CORE Healthy Aging Initiative (CHAI).
Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, discusses the importance of new medications to treat hepatitis C.
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses the biggest challenges associated with classifying and treating skin and soft tissue infections.
Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains why it’s important for individuals to know that they are infected with hepatitis C, although they may be asymptomatic.
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses which skin and soft tissue infections (SSTIs) are likely to be drug-resistant.
Oluwatoyin (Toyin) Adeyemi, MD, attending physician of infectious diseases at Cook County Health and Hospital System, discusses the Centers for Disease Control and Prevention’s (CDC) sexually transmitted disease (STD) testing guidelines.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses whether or not the prevalence of Powassan virus is increasing in humans.
Kerry LaPlante, professor of Pharmacy, University of Rhode Island, adjunct professor of Medicine, Brown University, director of the Rhode Island Infectious Diseases Research Program, and Infectious Diseases Pharmacotherapy Specialist, Providence Veterans Medical Center, discusses how pharmacists and physicians can work together in the hospital setting to optimize patient care.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses routine testing for Powassan virus.
Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, discusses efforts to understand the Zika virus.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses the treatment of Powassan virus.
Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, discusses Zika response at NYU Langone Medical Center.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses the differential diagnosis of Powassan virus.
Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, discusses Zika virus diagnostics.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, explains why it is important for healthcare practitioners to be aware of Powassan virus.
Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, explains how hospitals and healthcare systems can identify where resources need to be allocated when preparing for Zika outbreaks.
Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, talks about prevalence of Zika in pregnant women in New York.
Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses the prevalence of Powassan virus in humans in the United States.
Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses the value his research team’s findings will bring to healthcare practitioners.
Rita Olans, DNP, CPNP-PC, APRN-BC, assistant professor at MGH Institute of Health Professions, discusses how Infectious Disease specialists, pharmacists, and nurses can work together on antimicrobial stewardship.
Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses the clinical significance of his studies regarding the national prevalence of multidrug-resistant organisms.
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses push and pull incentives that drive antibiotic development.
Vikas Gupta, PharmD, BCPS, director of Clinical Strategy at Becton Dickinson, discusses the results of his research into the national prevalence of multidrug-resistant organisms.
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses global and national initiatives for the development of new antibiotics.
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, explains the economics of antimicrobial development.
Lauri A. Hicks, DO, captain, US Public Health Service, director, Office of Antibiotic Stewardship, medical director, Get Smart: Know When Antibiotics Work, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, examines the threat that antibiotic resistance poses to modern medicine.
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses the economic opportunities driving the development of new pharmaceuticals.
